[go: up one dir, main page]

WO1996036239A1 - Produit alimentaire et procede - Google Patents

Produit alimentaire et procede Download PDF

Info

Publication number
WO1996036239A1
WO1996036239A1 PCT/NZ1996/000039 NZ9600039W WO9636239A1 WO 1996036239 A1 WO1996036239 A1 WO 1996036239A1 NZ 9600039 W NZ9600039 W NZ 9600039W WO 9636239 A1 WO9636239 A1 WO 9636239A1
Authority
WO
WIPO (PCT)
Prior art keywords
casein
milk
product
allele
derived
Prior art date
Application number
PCT/NZ1996/000039
Other languages
English (en)
Inventor
Corran Norman Stuart Mclachlan
Original Assignee
Corran Norman Stuart Mclachlan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corran Norman Stuart Mclachlan filed Critical Corran Norman Stuart Mclachlan
Priority to DK96912338T priority Critical patent/DK0871366T3/da
Priority to CA2217820A priority patent/CA2217820C/fr
Priority to NZ306584A priority patent/NZ306584A/en
Priority to DE69634831T priority patent/DE69634831T2/de
Priority to AT96912338T priority patent/ATE297125T1/de
Priority to AU55108/96A priority patent/AU723396B2/en
Priority to EP96912338A priority patent/EP0871366B8/fr
Publication of WO1996036239A1 publication Critical patent/WO1996036239A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/40—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds characterised by the dairy products used
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/20—Meat products; Meat meal; Preparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to the removal, or the production of immunoglobulins against, immunosuppressant substances present, or, produced from the milk of animals of the genus Bos, and more particularly the domestic dairy species of the group Bos taurus and their crosses with the group Bos Indicus, which are used for milk production, and which contain specific casein alleles.
  • Immunoglobulins are present in the serum and mammary secretions of all mammalian species as part of the immune defence system of the animal.
  • the immunoglobulins are also known as antibodies and are produced by the body's immune system in response to the presence of substances called antigens, including a wide range of molecules, bacteria, viruses, cells and particles that do not express specific markers of 'self called histocompatibility antigens.
  • Molecular antigens are largely peptides, proteins and carbohydrates.
  • the classic immune response involves the production of antibodies capable of neutralising these antigens.
  • antigen is now widely used to indicate any molecule that can be specifically recognised by the adaptive elements of the immune system, that is by both B cells, which produce immunoglobulins and T cells which release substances such as cytokines, (Immunology, 3rd Edition ,Ed. I Roitt, J Brostoff, D Male, Mosby, London, 1993).
  • immunoglobulins There are five classes, or isotypes, of immunoglobulins all of which have a similar basic structure, but have differences in their organisational structure as well as the amino acid sequences present and carbohydrate groups present.
  • immunoglobulins there are present related immune system proteins. These are known as complement and they are a complex group of proteins which assist the function of antibodies. Their properties are described in the above texts.
  • complement proteins
  • immunoglobulin proteins produce an "immune milk” or "health food” incorporating the immunoglobulin proteins, either as a result of stimulating the milk producer's immune system by the addition or injection of substances into the animal's body, either once or systematically, which result in an immune response, or by concentrating the small amounts of immunoglobulins that are naturally present in milk -derived products.
  • the immunoglobulins may be specific responses to the injection of pathogenic bacteria into the milk-producing animals.
  • Japanese patent (1988) JP 63-133941 Hori T, Nishimoto K, Kimura M, Yommazaki N, describes a process in which immunoglobulins are collected by ultrafiltration from whey, the by-product of cheese or casein manufacture.
  • the immunoglobulin content of powder derived from this process was found to contain about ten times the immunoglobulin content of dried human milk.
  • UK Patent Application (1987) GB 2 179 947 Monsan PFE, Thibault PA, Brossad C, Bruvier CSJ describes a process for the extraction of proteins, preferably lactoferrin or immunoglobulins from whey comprising concentration of the whey using ultrafiltration with a polysulphone membrane (with MW cut-off 25,000-50,000) followed by diafiltration.
  • the retentate is then subject to adsorption of the retained proteins by ion exchange treatment using a weak cationic carboxymethyl resin at pH 5-8.5 and preferably at 7-8; and elution at the same pH.
  • EP 0 102 831 A 1 Linggood MA, Porter P, Powell JR describes the immunisation of host animals with a range of E. Coli implicated in human gastroenteric disease and the production of immunoglobulins, and a synthetic milk containing the immunoglobulins that are specific responses to the inoculation of the host.
  • EP 0 336 694 Beck LR describes a process for extracting an anti-inflammatory factor from cow or ewe milk, taken from animals that have been previously immunised by the administration of bacterial antigens. The anti-inflammatory factor is then extracted from whey that has been subjected to ion-exchange chromatography and molecular sieve chromatography.
  • the anti-hypertension factor is isolated by (1) removing from the milk molecules having a molecular weight greater than 10,000 daltons;(2) fractionating by ion-exchange chromatography the effluent to obtain a negatively charged fraction;(3) fractionating the negatively charged material eluted from the ion-exchange column using molecular sieve chromatography and isolating the hypertensive fraction from the latter step by isoelectric precipitation.
  • ⁇ -casein A 1 Allele is a term used herein in reference to one of the variant forms of the ⁇ - casein gene. Expression of the A 1 allele results in the production of " ⁇ -casein A 1 ".
  • ⁇ -casein A 1 it encompasses phenotypes resulting from either a homozygous or heterozygous state with respect to the ⁇ -casein A 1 allele.
  • Immunoglobulins and other immune proteins are used herein reference to milk obtained from an animal that has been immunised to selectively induce for formation of immunoglobulins and other immune proteins, directed against specific bacterial and/or viral pathogens or other foreign antigens that are known to cause diseases, in its milk, such milk being used to prevent disease, within the milk drinker, by fortifying the body's natural resistance against specific disease-causing antigens.
  • This invention is applicable to all products derived from cattle (live or dead) which products are substantially free of ⁇ -casein A 1 , or contains immune response proteins (including immunoglobulins) to ⁇ -casein A 1 .
  • This includes meat (including offal) blood and blood products (such as black pudding), casein, gelatin, milk and other dairy products, as well as manufactured products containing some or all of the foregoing examples (including whiteners for beverages that include some milk solids).
  • processed dairy product(s) is used herein to refer to dairy products derived from a source of bulk milk (ie from milk from more than one animal) and includes, but is not limited to:
  • confections such as chocolate
  • carbonated milk products including those with added phosphate and/or citrate
  • the invention provides a food product derived from animals which product is substantially free of the ⁇ -casein A 1 allele, or ⁇ -casein A 1 expressed therefrom.
  • the food product is meat or meat related, and more preferably is derived from an animal which is substantially free of the ⁇ -casein A 1 allele.
  • the food product is milk or other dairy product which is substantially free of ⁇ -casein A 1 .
  • the invention provides a meat or dairy food product which contains the ⁇ - casein A 2 allele in preference to the ⁇ -casein A 1 allele.
  • the invention provides a milk or other dairy product capable of minimising the onset of coronary heart disease characterised in that the milk or other dairy product is substantially free of ⁇ -casein A 1 , or its proteolytic or heat produced products.
  • the invention provides a process for producing milk or other dairy products which does not contain ⁇ -casein A 1 by testing the individual cows in a herd for the presence of the ⁇ -casein A 1 allele, or the presence of ⁇ -casein A 1 in their milk, and selectively culling from the herd those cows that test positive for the presence of the ⁇ -casein A 1 allele, or ⁇ -casein A 1 , until the bulk milk produced by the herd is substantially free of ⁇ -casein A 1 .
  • the invention provides a process for producing milk or other dairy products which does not contain ⁇ -casein A 1 by testing the individual cows in that herd for the presence of the ⁇ -casein A 1 allele or ⁇ -casein A 1 in their milk and subsequently employing breeding programmes which select against individual cows testing positive for the presence of the ⁇ - casein A 1 allele or ⁇ -casein A 1 until the bulk milk produced by the herd is substantially free of ⁇ -casein A 1 .
  • the invention provides a process for producing milk or other dairy products which does not contain ⁇ -casein A 1 by testing individual cows in a herd for the presence of the ⁇ -casein A 1 allele or ⁇ -casein A 1 in their milk and utilising genetic engineering procedures to remove the ⁇ -casein A 1 allele or inhibit expression of ⁇ -casein A 1 therefrom.
  • the invention provides milk and other dairy products which are substantially free of ⁇ -casein A 1 .
  • the dairy product is casein which is substantially free of ⁇ -casein A 1 .
  • This may be used as a food for animals or humans.
  • the invention provides a process for producing immunoglobulins and other immune response proteins, in cow's milk from animals not possessing the ⁇ -casein A 1 allele, or other commercial milk producing animals, to this allele, to counteract the immunosuppressant substances present that are produced from it, in commercial milking cows such as Holsteins, together with its blending with non-treated milk or the recovery of such immunoproteins.
  • the invention provides immunoglobulins and other immunoproteins produced as a result of inoculating commercial milk producing animals with ⁇ -casein A 1 , its proteolytic hydrolysis products, or fragments thereof produced by other means.
  • the invention provides blended milk obtained from mixing the product of the present invention with milk from animals possessing the ⁇ -casein A 1 allele as part of their genetic make-up either at the factory or by running a mixed herd of such animals.
  • the invention provides an immune milk (as herein described), such immune milk being substantially free of ⁇ -casein A 1 and/or produced from cattle or other commercial milking animals lacking the ⁇ -casein A 1 allele.
  • the immunoglobulins active against ⁇ -casein A 1 and its proteolytic products are recovered by ultrafiltration, ion exchange chromatography or an immunoadsorbent column.
  • the milk containing immunoglobulins active against ⁇ -casein A 1 and its proteolytic products may be in the form of whole milk, whole-milk powder, skim milk, skim milk powder, milk whey, yoghurt, cheese, or any other dairy product, or processed dairy product.
  • the invention provides immunoglobulins produced by treating a homozygous ⁇ -casein A 2 , B, or C, or heterozygous mixture of A 2 , B, and C, cow, with any inoculum to produce immunoglobulins in the milk from a cow that does not contain the immunosuppressant ⁇ -casein A 1 allele, ⁇ -casein A 1 , proteolytic fragments thereof or fragments thereof produced by other means.
  • the invention provides a method of reducing the onset of disease in an individual or a population which derives some of its food intake from milk or other dairy products by reducing or substantially eliminating the presence of ⁇ -casein A 1 in the diet of that population. This method is applicable to animals or humans.
  • the invention provides a method of reducing the onset of coronary heart disease in a human population which derives some of its food intake from milk or other dairy products by reducing or substantially eliminating the presence of ⁇ -casein A 1 in the diet of that population.
  • the invention provides a method of enhancing the immune response or decreasing the immune suppression of an individual or a population who or which derives some of his/her/its food intake from milk or other dairy products by reducing or substantially eliminating the presence of ⁇ -casein A 1 in the diet of that individual or that population.
  • the subject of this invention is the identification of the class of proteins responsible for a number of disorders such as coronary heart disease (and others as described above), their neutralisation in cow's milk and the production of an imunoglobulin capable of partially overcoming some of the deleterious effects they(or it) engender(s) on the human body.
  • This invention is not limited to a specific disease as the molecules concerned appear to act as immunosuppressants to the body's immune system and their removal can only enhance the general well-being of the individual while at the same time providing specific relief to individual's whose genetic make-up is such that contact with these proteins or protein will bring about a specific response such as atherosclerosis or other chronic disorders of the immune system.
  • Figure 1 is a graph entitled "The effect of food component on Ischaemic Heart Disease during 1985 for males aged 30-69". This shows the death rate of all ages per 100,000 of population, for a range of countries, based on the consumption of ⁇ -casein.
  • Figure 2 is a graph showing the effect of dairy protein consumption on Ischaemic Heart Disease for males aged 30-69 for the year 1985.
  • Figure 3 is a graph showing the effect of saturated fat consumption on Ischaemic Heart Disease for males aged 30-69 for the year 1985.
  • Figure 4 is a graph showing the effect of red meat consumption on Ischaemic Heart Disease for males aged 30-69 for the year 1985.
  • Figure 1 shows a very strong correlation between the consumption of the food component, identified as ⁇ -casein A 1 (discussed in more detail below), and the death rate.
  • ⁇ -casein A 1 the overall dairy protein consumption
  • Figure 3 the effect of saturated fat consumption
  • Figure 4 the consumption of red meat
  • Figure 4 come anywhere close to the very strong correlation with the inventor has identified in relation to the consumption of ⁇ -casein A 1 , both between countries and within countries.
  • Ischaemic Heart Disease death rates are found to correlate directly with the consumption of ⁇ -casein A 1 (Table 1A). In this instance the composition of the state dairy herd have remained virtually constant from the 1950's through to the 1980's.
  • Table 1A CHD nutritional risk factors, Federal Republic of Germany based on Schleswig-Holstein
  • Caseins constitute the majority of the milk proteins. Dairy cattle exhibit genetic polymo ⁇ hism in their proteins. The heterogeneity of the caseins is further complicated by the fact that they are the products of co-dominant allele autosomal genes. Some indication of their number, and the major product fragments into which they are split by proteolytic action of a variety of enzymes, is illustrated by the ⁇ -caseins in Table 2.
  • Bovine milk is an important source of proteins and other nutrients required by humans and the common domestic cattle species such as the Holstein have greater quantities of the A 1 allele than any other ⁇ -casein allele. Approximately 84 percent of the present American dairy herd is estimated to carry this allele.
  • a proteolytic enzyme plasmin which is naturally present in milk, and which is largely associated with the casein, is both increasingly active at higher temperatures and is quite heat stable. At 60 °C it has been demonstrated to have a relatively high rate of conversion of caseins, preferentially ⁇ -caseins to a range of proteolysis products. The increased mortality rate, demonstrated in Table 3, as a result of heating of the milk is presumed to be due to the formation of further proteolysis products, in addition to those naturally present, during the heating phase.
  • the preferred forms of this invention comprises the elimination from milk of ⁇ -casein A 1 or its proteolysis products, or protein fragments formed in any other way, either 'in vitro' or 'in vivo' and which have immunosuppressant properties, by the use of immunoglobulins raised against ⁇ -casein A 1 , the removal of ⁇ -casein A 1 and the inactivation of plasmin and other proteolytic enzymes.
  • the preferred forms of the invention represents a significant advance over existing treatments for atherosclerosis, and other generally chronic immunosuppressant diseases in that it will prevent their occurrence in the new-born who, when they are genetically susceptible, will in other circumstances develop the diseases as they age.
  • treatment for the pu ⁇ ose of this invention it is intended that the symptoms of the disorder be ameliorated or completely eliminated or, where genetic typing indicates that an individual is of high risk of developing a disorder, of ensuring that it does not develop.
  • the treatment consists of inoculating a milk producing animal, that does not possess the ⁇ -casein A 1 allele, preferably one that is homozygous for the ⁇ -casein A 2 allele, preferably one that produces commercially feasible quantities of milk, such as a cow, sheep, goat, or zebu with ⁇ -casein A 1 , or its proteolysis products, or fragments thereof, produced in any other manner, so that antigens to the foreign ⁇ -casein A 1 protein are produced.
  • These antigens may be produced either alone, or as part of a wider inoculation programme, to produce a milk with an enhanced antigen concentration as has been described in the Art.
  • This antigen enhanced milk is then added to 'normal' milk, or milk, or milk products, whose ⁇ -casein A 1 content has been reduced, using techniques known to those skilled in the Art, to counteract the presence of the immune suppressing ⁇ -casein A 1 derived material.
  • the above antigen(s) may be recovered by one of the processes known to the Art and used as a food supplement in its own right either alone or as a food additive.
  • immunoglobulins and other antigens are recovered from non ⁇ -casein A 1 containing milk by ultrafiltration, ion exchange chromatography either singly, or in combination, or by use of a suitable immunoadsorbent column, comprising an insoluble carrier material to which is bound a low-affinity monoclonal antibody specific to one or more milk immunoglobulins but not specific to any other common constituent of milk.
  • a suitable immunoadsorbent column comprising an insoluble carrier material to which is bound a low-affinity monoclonal antibody specific to one or more milk immunoglobulins but not specific to any other common constituent of milk.
  • Such milk may having been derived from an animal that has been inoculated with a vaccine derived from a bacteria such as E. coli, for example, or which has been inoculated with 'bacterial antigens', as described in the Art.
  • enhanced quantities of antigens are produced as a result of the inoculation, or inoculation programme of ⁇ -casein A'-free animals, to provide a milk product with all the claims as described in the prior Art.
  • This invention has the advantage over the existing Art that immunosuppressant proteins resulting from the presence of, or, derived from the ⁇ -casein A 1 allele are eliminated from the final milk, or milk-derived products.
  • Another alternative includes the use of a plasmin inhibitor, such as a protein like aprotonin, or other such inhibitors, known to the Art, which are added, either singly or in mixtures, to the milk, as part of the above invention, to suppress the formation of additional ⁇ -casein A 1 proteolysis products that would otherwise be formed during processing, and storage, prior to sale.
  • a plasmin inhibitor such as a protein like aprotonin, or other such inhibitors, known to the Art
  • a milk or other dairy product according to the invention can be produced by testing individual cows in a dairy herd for the presence of the ⁇ -casein A 1 allele, or for the presence of ⁇ -casein A 1 in milk, and then selectively culling those cows returning a positive result, until the bulk milk produced by the herd is substantially free of ⁇ -casein A 1 .
  • homozygous cattle containing the ⁇ -casein A 2 allele can be selectively bred so that the ⁇ -casein A 1 allele is eliminated from the herd.
  • An alternative approach to remove ⁇ -casein A 1 from bulk milk would involve separating cattle from existing herds which contain the ⁇ -casein A 1 allele, allowing the remainder of the herd (which are free of the ⁇ -casein A 1 allele) to be used for the production of bulk milk or other dairy products, and those cattle containing the A 1 allele to be used for the production of products for pu ⁇ oses other than human consumption.
  • Such a segregation process within a herd may be facilitated by the use of ear tags or the like to mark individual animals.
  • the invention provides a useful food product capable of increasing the health of an individual, or the health of a population.
  • the invention provides a method of enhancing the immune response of an individual or a population who or which derives some of his/her/its food intake from milk or other diary products, by reducing or substantially eliminating the presence of ⁇ -casein A 1 in the diet of that individual or that population.
  • the invention applies a method of reducing the onset of coronary heart disease in a human population which derives some of its food intake from milk or other diary products by reducing or substantially eliminating the presence of ⁇ -casein A 1 within the diet of that population.
  • ⁇ -casein A 1 By reducing or substantially eliminating the presence of ⁇ -casein A 1 in the diet of humans, it is believed that the immune response of an individual or a population may be enhanced, or immunosuppression reduced, increasing the general well-being of the individual or the population. It is believed that some individuals may be particularly susceptible to the presence of ⁇ -casein A , and it may be possible to develop a test for such susceptible individuals, and to recommend that they reduce or eliminate their consumption of milk or other diary products containing ⁇ -casein A 1 .
  • an alternative approach to remove the ⁇ - casein A 1 allele from a herd may be carried out.
  • Such an approach may include the screening of sperm to be used for the pu ⁇ ose of artificial insemination for the presence or absence of the ⁇ -casein A 1 allele and selecting against those sperm which contain this allele.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Meat, Egg Or Seafood Products (AREA)

Abstract

Cette invention se rapporte à un lait ou autre produit laitier, qui est capable de réduire au minimum l'apparition de maladies telles que les maladies cardiaques des coronaires ou d'améliorer la réponse immunitaire et qui est tiré d'animaux qui sont essentiellement dépourvus de l'allèle A1 de la caséine β. On peut produire du lait de mélange en testant et en éliminant les vaches qui sont positives au test de l'allèle A1 de la caséine β ou en produisant des immunoglobulines et d'autres protéines de réponse immunitaire contre cette allèle, dans du lait de vache provenant d'animaux ne possédant pas l'allèle A1 de la caséine β ou d'autres animaux producteurs de lait à usage commercial, afin de contrer les substances immunosuppressives présentes qui sont produites à partir de cette allèle, chez des bovins laitiers, par exemple de la race Holstein, conjointement aux mélanges de cette allèle avec du lait non traité ou à la récupération de ces immunoprotéines.
PCT/NZ1996/000039 1995-05-16 1996-05-09 Produit alimentaire et procede WO1996036239A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK96912338T DK0871366T3 (da) 1995-05-16 1996-05-09 Födevareprodukt og fremgangsmåde til fremstilling heraf
CA2217820A CA2217820C (fr) 1995-05-16 1996-05-09 Lait et produits laitiers pour la prevention ou le traitement de cardiopathies
NZ306584A NZ306584A (en) 1995-05-16 1996-05-09 Milk or dairy products derived from animals and which are free of beta casein
DE69634831T DE69634831T2 (de) 1995-05-16 1996-05-09 Nahrungsmittel und herstellungsverfahren
AT96912338T ATE297125T1 (de) 1995-05-16 1996-05-09 Nahrungsmittel und herstellungsverfahren
AU55108/96A AU723396B2 (en) 1995-05-16 1996-05-09 Food product and process
EP96912338A EP0871366B8 (fr) 1995-05-16 1996-05-09 Produit alimentaire et procede

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ27213395 1995-05-16
NZ272133 1995-05-16

Publications (1)

Publication Number Publication Date
WO1996036239A1 true WO1996036239A1 (fr) 1996-11-21

Family

ID=19925262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ1996/000039 WO1996036239A1 (fr) 1995-05-16 1996-05-09 Produit alimentaire et procede

Country Status (7)

Country Link
EP (1) EP0871366B8 (fr)
AT (1) ATE297125T1 (fr)
AU (1) AU723396B2 (fr)
CA (1) CA2217820C (fr)
DE (1) DE69634831T2 (fr)
DK (1) DK0871366T3 (fr)
WO (1) WO1996036239A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024371A1 (fr) * 1995-12-27 1997-07-10 Midia Limited Produit derive de lait provenant de mammiferes non humains, quasiment exempt de caseine beta, et utilisation
WO2003100074A2 (fr) 2002-05-24 2003-12-04 A2 Corporation Limited Methode de genotypage d'animaux
WO2004004450A1 (fr) 2002-07-03 2004-01-15 A2 Corporation Limited Procede destine a modifier la teneur en acides gras du lait
EP1196047A4 (fr) * 1999-06-29 2004-12-22 New Zealand Milk Inst Ltd Complements alimentaires prophylactiques a base de lait
EP1562629A4 (fr) * 2002-10-04 2007-08-29 A2 Corp Ltd Utilisations therapeutiques de la beta-caseine a2 et d'un complement alimentaire contenant de la beta-caseine a2
EP3003485B1 (fr) 2013-05-31 2019-05-15 The A2 Milk Company Limited Composition comprenant de la bêta-caséine a2 pour son utilisation dans la prévention d'une inflammation de l'intestin
EP3542805A1 (fr) 2013-07-12 2019-09-25 The A2 Milk Company Limited Bêta-caséine a2 et réduction ou prévention des symptômes de l'intolérance au lactose
US10568933B2 (en) 2013-08-23 2020-02-25 The A2 Milk Company Limited Beta-casein A2 and blood glucose levels
US10702580B2 (en) 2015-05-22 2020-07-07 The A2 Milk Company Limited Beta-casein A2 and antioxidant capacity
CN113260260A (zh) * 2018-12-20 2021-08-13 雀巢产品有限公司 确定和量化䏡蛋白胨含量和/或β-酪蛋白含量以及具有降低的β-酪蛋白衍生的䏡蛋白胨含量的营养组合物
US11504412B2 (en) 2016-03-30 2022-11-22 The A2 Milk Company Limited Beta-caseins and cognitive function
RU2784851C2 (ru) * 2013-05-31 2022-11-30 Зэ А2 Милк Компани Лимитед Бета-казеин а2 и предотвращение воспаления кишечника
US11925197B2 (en) 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631731A1 (fr) * 1993-06-30 1995-01-04 Bristol-Myers Squibb Company Hydrolysat partiel de protéines de lait, et procédé de préparation
AU7659094A (en) * 1993-10-12 1995-05-04 Viable Bioproducts Ltd. Nutritional drink
WO1996014577A1 (fr) * 1994-11-04 1996-05-17 The National Child Health Research Foundation Procede de selection de lait ou de produits laitiers non diabetogenes, et lait et produits laitiers ainsi selectionnes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631731A1 (fr) * 1993-06-30 1995-01-04 Bristol-Myers Squibb Company Hydrolysat partiel de protéines de lait, et procédé de préparation
AU7659094A (en) * 1993-10-12 1995-05-04 Viable Bioproducts Ltd. Nutritional drink
WO1996014577A1 (fr) * 1994-11-04 1996-05-17 The National Child Health Research Foundation Procede de selection de lait ou de produits laitiers non diabetogenes, et lait et produits laitiers ainsi selectionnes

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024371A1 (fr) * 1995-12-27 1997-07-10 Midia Limited Produit derive de lait provenant de mammiferes non humains, quasiment exempt de caseine beta, et utilisation
EP1196047A4 (fr) * 1999-06-29 2004-12-22 New Zealand Milk Inst Ltd Complements alimentaires prophylactiques a base de lait
WO2003100074A2 (fr) 2002-05-24 2003-12-04 A2 Corporation Limited Methode de genotypage d'animaux
AU2003234372B2 (en) * 2002-05-24 2009-09-17 The A2 Milk Company Limited Animal genotyping method
US7629119B2 (en) * 2002-05-24 2009-12-08 A2 Corporation Limited Animal genotyping method
WO2004004450A1 (fr) 2002-07-03 2004-01-15 A2 Corporation Limited Procede destine a modifier la teneur en acides gras du lait
JP2005531325A (ja) * 2002-07-03 2005-10-20 エイツー・コーポレーション・リミテッド 生乳の脂肪酸の組成を変える方法
CN100400672C (zh) * 2002-07-03 2008-07-09 A2有限公司 改变牛奶中脂肪酸组成的方法
US7851147B2 (en) 2002-07-03 2010-12-14 A2 Corporation Limited Method of determining fatty acid composition of milk
EP1562629A4 (fr) * 2002-10-04 2007-08-29 A2 Corp Ltd Utilisations therapeutiques de la beta-caseine a2 et d'un complement alimentaire contenant de la beta-caseine a2
CN100377740C (zh) * 2002-10-04 2008-04-02 A2有限公司 β－酪蛋白A2的治疗用途和含有β－酪蛋白A2的饮食添加剂
EP3542813A1 (fr) 2013-05-31 2019-09-25 The A2 Milk Company Limited Bêta-caséine a2 et prévention de l'inflammation des intestins
EP3003485B1 (fr) 2013-05-31 2019-05-15 The A2 Milk Company Limited Composition comprenant de la bêta-caséine a2 pour son utilisation dans la prévention d'une inflammation de l'intestin
US11911439B2 (en) 2013-05-31 2024-02-27 The A2 Milk Company Limited Beta-casein A2 and prevention of inflammation of the bowel
RU2784851C2 (ru) * 2013-05-31 2022-11-30 Зэ А2 Милк Компани Лимитед Бета-казеин а2 и предотвращение воспаления кишечника
EP3542805A1 (fr) 2013-07-12 2019-09-25 The A2 Milk Company Limited Bêta-caséine a2 et réduction ou prévention des symptômes de l'intolérance au lactose
RU2791693C2 (ru) * 2013-07-12 2023-03-13 Зэ А2 Милк Компани Лимитед Бета-казеин а2 и уменьшение или предотвращение симптомов непереносимости лактозы
EP3943100A1 (fr) 2013-08-23 2022-01-26 The A2 Milk Company Limited Bêta-caséine a2 et niveaux de glycémie
EP3035951B1 (fr) 2013-08-23 2021-09-15 The A2 Milk Company Limited Bêta-caséine a2 et niveaux de glycémie
RU2802806C1 (ru) * 2013-08-23 2023-09-04 Зэ А2 Милк Компани Лимитед Бета-казеин a2 и уровень глюкозы в крови
US10568933B2 (en) 2013-08-23 2020-02-25 The A2 Milk Company Limited Beta-casein A2 and blood glucose levels
US10702580B2 (en) 2015-05-22 2020-07-07 The A2 Milk Company Limited Beta-casein A2 and antioxidant capacity
US11504412B2 (en) 2016-03-30 2022-11-22 The A2 Milk Company Limited Beta-caseins and cognitive function
US11925197B2 (en) 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota
CN113260260A (zh) * 2018-12-20 2021-08-13 雀巢产品有限公司 确定和量化䏡蛋白胨含量和/或β-酪蛋白含量以及具有降低的β-酪蛋白衍生的䏡蛋白胨含量的营养组合物

Also Published As

Publication number Publication date
CA2217820C (fr) 2011-03-01
DE69634831D1 (de) 2005-07-14
EP0871366A1 (fr) 1998-10-21
CA2217820A1 (fr) 1996-11-21
EP0871366B1 (fr) 2005-06-08
EP0871366A4 (fr) 2001-05-02
EP0871366B8 (fr) 2005-08-03
DE69634831T2 (de) 2006-06-29
DK0871366T3 (da) 2005-10-10
AU5510896A (en) 1996-11-29
ATE297125T1 (de) 2005-06-15
AU723396B2 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
JP6693807B2 (ja) 乳製品および調製方法
Petschow et al. Response of bifidobacterium species to growth promoters in human and cow milk
EP3232796B1 (fr) Yogourt avec des protéines de lactosérum natives et leurs procédés de production
US20070162988A1 (en) Milk and milk products for preventing or treating heart disease
CA2217820C (fr) Lait et produits laitiers pour la prevention ou le traitement de cardiopathies
Sakandar et al. Camel milk and its allied health claims: A review
Abd El-Aziz et al. Physicochemical properties and health benefits of camel milk and its applications in dairy products: A review
NL2002768C2 (en) Satiety inducing milk product.
De Boer From milk by-products to milk ingredients: upgrading the cycle
Goswami et al. Implication of functional ingredients of goat milk to develop functional foods
Ahmad Buffalo milk
Patel et al. A comprehensive review on the properties of camel milk and milk products.
PREMJIBHAI Isolation and purification of ACE-inhibitory peptides derived from fermented surti goat milk
Boylston Byproducts from butter and cheese processing
US20020007497A1 (en) Food product and process
AU2008203187A1 (en) Bovine genotype testing for beta-caseins
Kelly et al. From Farm to Table: The Science of Milk and Dairy Products
Hebatallah et al. Buttermilk: one of the oldest functional foods
AU2006233196B2 (en) Enriched milk products
NZ306584A (en) Milk or dairy products derived from animals and which are free of beta casein
CN101014253A (zh) 人乳强化剂及其生产方法
Khosravi–Darani¹ et al. Probiotic dairy dessert from camel milk–A review
JP3411965B2 (ja) ポリアミン含有組成物の製造方法
Morgan Human milk
Brooker Electron microscopy of normal and defective Cottage cheese curd

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 306584

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2217820

Country of ref document: CA

Ref country code: CA

Ref document number: 2217820

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996912338

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996912338

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996912338

Country of ref document: EP